Predictive value of anemia for tuberculosis in HIV-infected patients in sub-saharan africa: An indication for routine microbiological investigation using new rapid assays

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 1, 2014, Pages 33-40

  Kerkhoff, Andrew D ^a,b   Wood, Robin ^b   Vogt, Monica ^b   Lawn, Stephen D ^b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Africa; anemia; antiretroviral; diagnosis; hemoglobin; HIV; LAM; tuberculosis; urine; Xpert MTB RIF

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEMOGLOBIN; LIPOARABINOMANNAN;

ADULT; AFRICA SOUTH OF THE SAHARA; ANEMIA; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FLUORESCENCE MICROSCOPY; HEMATOLOGY ANALYZER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CULTURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SOUTH AFRICA; SPUTUM ANALYSIS; SPUTUM CYTODIAGNOSIS; URINALYSIS; WORLD HEALTH ORGANIZATION;

ADULT; AFRICA; ANEMIA; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MALE; PREGNANCY; PREVALENCE; SOUTH AFRICA; SPUTUM; TUBERCULOSIS;

EID: 84898541893     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000091     Document Type: Article

References (51)

1. O'Brien ME, Kupka R, Msamanga GI, et al. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr. 2005;40: 219-225.
2. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999;13:943-950.
3. Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2001;26:28-35.
4. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004;116:27-43.
5. Breitbart W, McDonald MV, Rosenfeld B, et al. Fatigue in ambulatory AIDS patients. J Pain Symptom Manage. 1998;15:159-167.
6. Revicki DA, Brown RE, Henry DH, et al. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr. 1994;7:474-484.
7. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIVinfected patients: impact on quality of life. Int J STD AIDS. 2000;11:659-665.
8. Morfeldt-Månson L, Böttiger B, Nilsson B, et al. Clinical signs and laboratory markers in predicting progression to AIDS in HIV-1 infected patients. Scand J Infect Dis. 1991;23:443-449.
9. Moore RD, Creagh-Kirk T, Keruly J, et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Arch Intern Med. 1991;151:981.
10. De Santis GC, Brunetta DM, Vilar FC, et al. Hematological abnormalities in HIV-infected patients. Int J Infect Dis. 2011;15:e808-e811.
11. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91:301-308.
12. van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011;56:349-355.
13. Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378:57-72.
14. McDermid JM, Hennig BJ, van der Sande M, et al. Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: an 11-year retrospective cohort study. BMC Infect Dis. 2013;13:1-1.
15. Mugusi FM, Mehta S, Villamor E, et al. Factors associated with mortality in HIV-infected and uninfected patients with pulmonary tuberculosis. BMC Public Health. 2009;9:409.
16. Kourbatova EV, Borodulin BE, Borodulina EA, et al. Risk factors for mortality among adult patients with newly diagnosed tuberculosis in Samara, Russia. Int J Tuberc Lung Dis. 2006;10:1224-1230.
17. Ciglenecki I, Glynn JR, Mwinga A, et al. Population differences in death rates in HIV-positive patients with tuberculosis. Int J Tuberc Lung Dis. 2007;11:1121-1128.
18. Kendon MA, Knight S, Ross A, et al. Timing of antiretroviral therapy initiation in adults with HIV-associated tuberculosis: outcomes of therapy in an urban hospital in KwaZulu-Natal. S Afr Med J. 2012; 102:931-935.
19. Russell EC, Charalambous S, Pemba L, et al. Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health. 2010;10:433.
20. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605-1612.
21. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148.
22. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007;21:335-341.
23. Gupta A, Wood R, Kaplan R, et al. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013;8:e55824.
24. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8:e1000391.
25. Lawn SD, Kerkhoff AD, Pahlana P, et al. Diagnostic yield of tuberculosis using sputum induction in HIV-positive patients before antiretroviral therapy. Int J Tuberc Lung Dis. 2012;16:1354-1357.
26. Dawson R, Masuka P, Edwards DJ, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis. 2010;14:52-58.
27. Lawn SD, Kerkhoff AD, Vogt M, et al. Diagnostic accuracy of a lowcost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12:201-209.
28. Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis. 2012;54:1071-1079.
29. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011;8: e1001067.
30. World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Geneva: Vitamin and Mineral Nutrition Information System. Geneva, Switzerland: World Health Organization; 2011. (WHO/NMH/NHD/MNM/11.1) Available at: http://www.who.int/vmnis/indicators/ haemoglobin.pdf. 2011.
31. Lewis DK, Whitty CJM, Walsh AL, et al. Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence. Trans R Soc Trop Med Hyg. 2005;99:561-567.
32. Masaisa F, Gahutu JB, Mukiibi J, et al. Anemia in human immunodeficiency virus-infected and uninfected women in Rwanda. Am J Trop Med Hyg. 2011;84:456-460.
33. Subbaraman R, Devaleenal B, Selvamuthu P, et al. Factors associated with anaemia in HIV-infected individuals in southern India. Int J STD AIDS. 2009;20:489-492.
34. Singh KJ, Ahluwalia G, Sharma SK, et al. Significance of haematological manifestations in patients with tuberculosis. J Assoc Physicians India. 2001;49:788, 790-794.
35. Lee SW, Kang YA, Yoon YS, et al. The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci. 2006;21:1028-1032.
36. Isanaka S, Mugusi F, Urassa W, et al. Iron deficiency and anemia predict mortality in patients with tuberculosis. J Nutr. 2012;142:350-357.
37. Marshall JB. Tuberculosis of the gastrointestinal tract and peritoneum. Am J Gastroenterol. 1993;88:989-999.
38. Viallard JF, Parrens M, Boiron JM, et al. Reversible myelofibrosis induced by tuberculosis. Clin Infect Dis. 2002;34:1641-1643.
39. Hungund BR, Sangolli SS, Bannur HB, et al. Blood and bone marrow findings in tuberculosis in adults-A cross sectional study. Al Ameen J Med Sci. 2012;5:362-366.
40. Kuo PH, Yang PC, Kuo SS, et al. Severe immune hemolytic anemia in disseminated tuberculosis with response to antituberculosis therapy. Chest. 2001;119:1961-1963.
41. Murray HW. Transient autoimmune hemolytic anemia and pulmonary tuberculosis. N Engl J Med. 1978;299:488.
42. van Lettow M, West CE, van der Meer JWM, et al. Low plasma selenium concentrations, high plasma human immunodeficiency virus load and high interleukin-6 concentrations are risk factors associated with anemia in adults presenting with pulmonary tuberculosis in Zomba district, Malawi Eur J Clin Nutr. 2005;59:526-532.
43. Sharma MP, Bhatia V. Abdominal tuberculosis. Indian J Med Res. 2004; 120:305-315.
44. Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004;38:1454-1463.
45. Semba RD, Shah N, Klein RS, et al. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and uninfected women. Clin Infect Dis. 2002;34:260-266.
46. Nglazi MD, Kaplan R, Wood R, et al. Identification of losses to follow-up in acommunity-based antiretroviral therapy clinic in South Africa using a computerized pharmacytracking system. BMC Infect Dis. 2010;10:329.
47. Fox MP, Brennan A, Maskew M, et al. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010;15:405-413.
48. Lawn SD, Kerkhoff AD, Vogt M, et al. HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays. BMC Med. 2013;11: 231.
49. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis. 2012;12:103.
50. Lawn SD, Dheda K, Kerkhoff AD, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis. 2013;13:407.
51. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13:349-361.